ATC code none PubChem CID 158385 KEGG D05080 Molar mass 1,148.403 g/mol | CAS Number 156436-89-4 ChemSpider 139341 ChEBI CHEBI:50161 | |
 | ||
Pronounce medical words motexafin gadolinium
Motexafin gadolinium (proposed tradename Xcytrin) is an inhibitor of thioredoxin reductase and ribonucleotide reductase. It has been proposed as a possible chemotherapeutic agent in the treatment of brain metastases.
Contents
History
On May 9, 2006, a New Drug Application was submitted to the United States Food and Drug Administration (FDA) by Pharmacyclics, Inc.
On December 2007, the FDA issued a not approvable letter for motexafin gadolinium.
References
Motexafin gadolinium Wikipedia(Text) CC BY-SA